Parameters | Value (mean/rate) | SE | Range | Distribution | References |
---|---|---|---|---|---|
Survival and transition probabilities | |||||
 CAPD to HD | 0.067 | 0.020 | 0.058–0.081 | Beta | Surendra et al. [16] |
 HD to CAPD | 0.007 | 0.002 | 0.002–0.001 | Beta | Surendra et al. [16] |
 Peritonitis complication | 0.200 | 0.010 | 0.180–0.220 | Beta | Gupta et al. [17] |
 Vascular access complication | 0.100 | 0.013 | 0.075–0.125 | Beta | Xue et al. [18] |
CAPD (survival) | |||||
 Year 1 | 0.800 | 0.006 | 0.788–0.812 | Beta | Gunawan and Sakti [19] |
 Year 2 | 0.720 | 0.008 | 0.704–0.736 | Beta | Assumed* |
 Year 3 | 0.600 | 0.009 | 0.582–0.617 | Beta | Gunawan and Sakti [19] |
 Year 4 | 0.570 | 0.009 | 0.542–0.577 | Beta | Assumed |
 Year 5 | 0.520 | 0.009 | 0.502–0.537 | Beta | Gunawan and Sakti [19] |
HD (survival) | |||||
 Year 1 | 0.824 | 0.006 | 0.811–0.837 | Beta | Afiatin et al., [20] |
 Year 2 | 0.706 | 0.008 | 0.690–0.722 | Beta | Afiatin et al., [20] |
 Year 3 | 0.621 | 0.009 | 0.604–0.638 | Beta | Afiatin et al., [20] |
 Year 4 | 0.580 | 0.009 | 0.563–0.598 | Beta | Afiatin et al., [20] |
 Year 5 | 0.553 | 0.009 | 0.536–0.571 | Beta | Afiatin et al., [20] |
Direct medical costs | |||||
 Pre-dialysis set-up_CAPD | 16,010,564 | 165,562 | 15,686,062–16,335,065 | Gamma | Hospital billing |
 Pre-dialysis set-up_HD | 16,150,823 | 2,337,311 | 11,569,693–20,731,952 | Gamma | Hospital billing |
 DMC_CAPD | 142,328,780 | 6,008,598 | 135,173,358–149,484,201 | Gamma | Hospital billing |
 DMC_HD | 120,289,134 | 3,650,725 | 108,512,280–132,065,987 | Gamma | Hospital billing |
 CC_CAPD | 9,592,093 | 4,178,178 | 1,402,864–17,781,321 | Gamma | Hospital billing |
 CC_HD | 27,173,929 | 7,158,016 | 13,144,217–41,203,640 | Gamma | Hospital billing |
Direct non-medical costs | |||||
 DNMC_CAPD | 5,266,455 | 1,353,606 | 2,613,387–7,919,522 | Gamma | Interview |
 DNMC_HD | 10,083,572 | 950,959 | 8,219,690–11,947,453 | Gamma | Interview |
Indirect costs | |||||
 ID_CAPD | 7,196,578 | 1,535,788 | 4,186,434–10,206,722 | Gamma | Interview |
 ID_HD | 10,858,993 | 968,098 | 8,961,519–12,756,466 | Gamma | Interview |
Utility | |||||
 U_CAPD | 0.81 | 0.04 | 0.73–0.88 | Beta | Interview |
 U_HD | 0.65 | 0.03 | 0.60–0.71 | Beta | Interview |
 U_CAPD_com | 0.31 | 0.09 | 0.13–0.39 | Beta | Afiatin et al. [11], |
 U_HD_com | 0.37 | 0.11 | 0.15–0.58 | Beta | Afiatin et al. [11], |
Discounting | |||||
 Cost | 3% |  |  |  | HTA guideline [17] |
 Effect | 3% |  |  |  | HTA guideline [17] |